繁體
简体中文
繁體中文

HUDSON CAPITAL INC HUSN

等待開盤 03-26 09:30:00 美东时间

1.66

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 1.66
  • 總市值 546.02万
  • 52周最高 495000.0113
  • 市盈率 --
  • 換手率 0.00%
  • 52周最低 70000.00
  • 委 比 0.00%
  • 總股本 328.93万
  • 歷史最高 36355000.8263
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 70000.00
  • 每 手 1
  • 風險率 0.00%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

    Serina Therapeutics reported financial results for 2025, highlighting FDA clearance for SER-252, initiation of its Phase 1b trial, and a $30 million private placement financing. The company achieved operating expenses of $24.2 million, net loss of $19.4 million, and ended with $3.1 million in cash. Key milestones include advancing SER-252 for Parkinson's disease, securing new funding, and strengthening the balance sheet for upcoming clinical tria...

    03-25 20:20

  • Serina Therapeutics to Present at the 38th Annual Roth Conference

    Serina Therapeutics CEO Steve Ledger will discuss the company's proprietary POZ Platform technology and pipeline at the 38th Roth Conference. The company is advancing drug candidates for neurological diseases using its polymer-based delivery system, which enhances drug efficacy and safety. Serina also collaborates with Pfizer on lipid nanoparticle drug delivery. Key product SER-252 aims to provide continuous dopaminergic stimulation for Parkinson...

    03-24 10:00

  • HMH Holding Inc. Announces Launch of Initial Public Offering

    HMH Holding Inc. has launched an IPO of 10,520,000 Class A common shares, with an option for underwriters to purchase an additional 1,578,000 shares. The offering price is expected to range from $19.00 to $22.00 per share, with the shares to be listed on Nasdaq under the ticker "HMH." J.P. Morgan, Piper Sandler, and Evercore ISI are joint lead book-running managers, while Citigroup and DNB Carnegie are joint book-running managers. Stifel, Nordea,...

    03-23 20:09

  • Erie Indemnity sets April 21, 2026 annual meeting date

    Erie Indemnity sets April 21, 2026 annual meeting date Erie Indemnity’s board approved the record date of Feb. 20, 2026 for the annual meeting and related materials. The board set the annual meeting for April 21, 2026 and specified that only Class B common stockholders may vote. Directors accepted t

    03-20 20:02

  • Sanofi SA Stock (SNY) Moved Up by 3.07% on Mar 19: Key Drivers Unveiled

    • Sanofi's venglustat received FDA Breakthrough Therapy designation for Gaucher disease. • Dupixent gained FDA approval for allergic fungal rhinosinusitis. • Sanofi announced a €1 billion share buyback and opened a China innovation center.

    03-19 19:15

  • UPDATE 1-Germany sets mid-April deadline for troubled fighter project with France

    UPDATE 1-Germany sets mid-April deadline for troubled fighter project with France Adds Macron comments, background in paragraphs 6-9 BERLIN, March 19 (Reuters) - The German government has set a mid-April deadline for reaching an agreement with France on the crisis-hit ‌FCAS fighter programme, a gove

    03-19 18:21

  • WRAPUP 5-Central banks hawkish but cautious in war's shadow

    WRAPUP 5-Central banks hawkish but cautious in war's shadow Adds SNB and Swedish Riksbank decisions in paragraph 12 US, Canada, Japan keep rates on hold amid inflation concerns Central banks warn risk of inflation if fuel costs remain high BOJ chief keeps alive expectation of near-term rate hike Bra

    03-19 07:37

  • Boyd Group Q4 adjusted net earnings more than doubled to USD 22.77 million

    Boyd Group Q4 adjusted net earnings more than doubled to USD 22.77 million Boyd Group published a fourth-quarter and full-year 2025 earnings release, reporting Q4 sales of USD 793.85 million, up 5.5%. Full-year sales rose 2.4% to USD 3.14 billion, as USD 94.2 million of incremental sales from 119 ne

    03-18 18:01

  • Sanofi’s venglustat granted U.S. breakthrough therapy status for type 3 Gaucher disease

    The U.S. Food and Drug Administration has granted breakthrough therapy designation to Sanofi’s (SNY) venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treat...

    03-18 14:12

  • HPE Introduces AI Factory, Supercomputer Enhancement In Partnership With Nvidia

    HPE (NYSE: HPE) today announced significant innovations to the NVIDIA AI Computing by HPE portfolio focused on large-scale AI factories and supercomputers that enable customers to scale, deploy efficiently, and gain

    03-17 04:42